Connecting you with your industry every day
A new ranking reveals the lobbying firms most used by pharmaceutical companies to press their case with the Government - with one firm attracting significantly more clients than any other
Created to navigate the increasingly complex landscape of public health priorities, Government policy, public funding and the private market
Tens of thousands gain access to diabetes medications after Pharmac expands eligibility for funded treatments
Additional biosimilar brands targeting this lucrative franchise have been approved ahead of the PBAC's meeting next month which will consider them for PBS listing
After a significant stretch as one of industry's longest-serving ANZ Country Leaders this former GM has landed a new role
Three departures including one redundancy as leaders across industry move on, taking decades of company history with them
The new radiopharma is backed by an investment syndicate led by 'Twiggy' Forrest's Tenmile with a mission to develop significant new medicines for hard-to-treat cancers
Op-Ed: The return of Healthcare Marketing to Australia's prestigious Effie Awards means so much more than another gong for industry
All high-strength formulations of this drug are set to be discontinued in Australia, with the TGA implementing Serious Scarcity Substitution to support ongoing patient access
DBG Health has severed ties with Sam Wood, who faces two domestic violence charges, after it acquired the reality TV star’s exercise and nutrition program
Following an extended back-and-forth with the PBAC, this pharma appears to be progressing its new treatment towards a PBS listing
mRNA powerhouse and Australia's national science agency launched a five-year strategic collaboration at Moderna's Melbourne plant this morning, with the first project unveiled
While most specialists view MSLs positively almost a third describe their interactions as average or poor and almost one in three can't spot the difference between an MSL and Sales Rep
Company catches up with how patients who are using this drug in the real world by kicking off a new trial and the upside could be a hike in profits
Slapped with the most serious Code of Conduct breach and reprimanded for a "significant failure" on transparency
The new loans carry an interest rate significantly higher than the ones being replaced
Two well-known cancer drugs that historically generated around $50 million in annual sales each will be removed from the Australian market in the first half of 2027
Australia's regulator has handed out a dozen fines for offences involving Eli Lilly's Mounjaro and Olumiant, along with a number of other drugs
This newcomer is set to disrupt a longtime rivalry between two Big Pharmas in a highly competitive space after stunning phase 3 results
Half of the cancer patients who received a one-shot therapy remain progression free after five years, follow-up results show
With only one quarter remaining of 2026, companies are already lining up their talent for next year with a flurry of promotions and new hires
Exclusive global partnership to co-develop and co-promote a potential game-changing therapy across a range of kidney and liver diseases
A new competitor to what was once the top-selling drug on the PBS plus approval for the first generic of a drug first registered in Australia in 1991
ASX-listed biopharma has gone into voluntary administration, seeking to preserve its intellectual property after a catastrophic Phase 3 trial failure
While the exact number of roles or business functions impacted has not been officially disclosed, it’s understood redundancies have hit the commercial team
Roche is delivering the first innovative solution of its kind to Australian patients with the company already heading to the PBAC for reimbursement
Now in its third year, the industry-specific list, compiled by Great Places to Work has doubled in size, with 10 companies making the cut in 2026
Even though three 'first new brands' hit onto the PBS at the start of October in competition with this $20M drug, there's been no price cut